Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Castle Biosciences Inc(CSTL)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for CSTL
09/25/2026: CSTL (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Castle Biosciences is a specialized diagnostics company that provides gene expression profile tests to help clinicians assess the risk of skin cancers and GI conditions. The company's strengths lie in its clinically validated product portfolio and a dedicated sales force that has established a solid presence among specialists. Its primary growth story revolves around the continued adoption of its dermatological tests and the successful expansion into gastroenterology via its TissueCypher platform. Investors face risks related to reimbursement coverage, regulatory oversight of diagnostics, and intense competition. This stock is best suited for growth-oriented investors who can tolerate volatility and are monitoring the company's progress toward sustained profitability.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The company exhibits high revenue growth rates and addresses large, underpenetrated markets in specialized diagnostics. |
| Momentum investor | Mixed fit | Performance is highly sensitive to clinical milestones and reimbursement news, requiring a positive trend signal. |
| Value investor | Weak fit | The company prioritizes aggressive growth over immediate earnings, making traditional valuation metrics challenging. |
| Dividend investor | Weak fit | Castle Biosciences does not pay a dividend and is not expected to do so in the near future. |
| Low-risk investor | Weak fit | High exposure to regulatory, reimbursement, and market volatility risks makes this unsuitable for conservative portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock often reacts sharply to regulatory developments and earnings reports. |
| Valuation risk | Medium / high | Growth stocks with high multiples are sensitive to shifts in interest rates and investor risk appetite. |
| Competition risk (diagnostic labs) | Medium | Established players with extensive distribution networks could challenge Castle's niche market segments. |
| Business quality | Medium | While the company has a strong product-market fit, it is still evolving its operational infrastructure. |
| Dividend income | Low / none | The company does not provide income, relying on capital growth instead. |
| Execution risk | Medium | Success depends on the ongoing ability to gain payer coverage and educate clinicians. |
Price Behavior
Downtrend
The stock has experienced a sustained decline in price over recent periods.
Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit 19.19% | Avg. Invested days 42 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 09/25/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.09B USD | Price to earnings Ratio - | 1Y Target Price 45.11 |
Price to earnings Ratio - | 1Y Target Price 45.11 | ||
Volume (30-day avg) 357.6K shares | Beta 1 | 52 Weeks Range 17.72 - 44.28 | Updated Date 09/27/2026 |
52 Weeks Range 17.72 - 44.28 | Updated Date 09/27/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.64 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Dermatology Diagnostics | Revenue from DecisionDx-Melanoma, DecisionDx-SCC, and other skin cancer tests. | The primary revenue driver comes from selling proprietary cancer risk tests to dermatologists. |
| Gastroenterology Diagnostics | Revenue from the TissueCypher test for Barrett's esophagus. | This is a key growth area where the company is trying to establish a foothold in GI diagnostics. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Valuation
Trailing PE - | Forward PE - | Enterprise Value 836.02M | Price to Sales(TTM) 3.06 |
Enterprise Value 836.02M | Price to Sales(TTM) 3.06 | ||
Enterprise Value to Revenue 2.34 | Enterprise Value to EBITDA 42.95 | Shares Outstanding 30.55M | Shares Floating 27.15M |
Shares Outstanding 30.55M | Shares Floating 27.15M | ||
Percent Insiders 2.42 | Percent Institutions 91.01 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Castle Biosciences Inc
Exchange NASDAQ | Headquarters Friendswood, TX, United States | ||
IPO Launch date 2019-07-25 | Founder, CEO, President & Director Mr. Derek J. Maetzold | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 1002 | Website https://castlebiosciences.com |
Full time employees 1002 | Website https://castlebiosciences.com | ||
Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), atopic dermatitis (AD), and uveal melanoma. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the likelihood of a positive sentinel lymph node and the risk of metastasis for patients with invasive cutaneous melanoma; TissueCypher, a risk stratification spatialomics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, and low-grade dysplasia BE; AdvanceAD-Tx, a non-invasive GEP test which is designed to guide systemic treatment selection for patients aged 12 years and older with moderateto-severe AD; DecisionDx-SCC, a GEP test for cutaneous squamous cell carcinoma; and MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions. It also provides DecisionDx-UM, a risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma. The company offers its products to dermatology and gastroenterology markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.